HNSN Hansen Medical, Inc. (MM)

BOSTON, MA will showcase its new Cohesion(TM) 3D Visualization Interface* alongside its Sensei(TM) Robotic Catheter System here at the 13th Annual Boston Atrial Fibrillation (AF) Symposium, January 17-19, 2008. The newly integrated electrophysiology (EP) solution offers physicians a software interface between the company's next generation robotic technology and the St. Jude Medical EnSite(TM) System. Although the CoHesion Interface is already commercially available in the European Union, it is currently undergoing 510(k) review by the U.S. Food & Drug Administration (FDA), and is not yet commercially available in the United States.

The CoHesion Interface is designed to allow physicians to remotely manipulate catheters with more accuracy because it provides 3D information regarding the actual position of catheters inside a patient's heart. These features are expected to make complex EP procedures more efficient by enabling physicians to operate in a 3D navigation and mapping environment with robotic control over catheter placement in specific locations.

"This integrated platform solution is another step in our ongoing strategy to expand our offering to electrophysiologists worldwide and position Hansen Medical at the forefront of finding solutions to help physicians benefit their patients by effectively and safely treating heart disease earlier," said Frederic Moll, M.D., founder and CEO of Hansen Medical. "By integrating our Sensei system with St. Jude Medical's EnSite system, we are augmenting the ability of electrophysiologists to more easily move catheters within the 3D cardiac space so they can perform complex procedures with more confidence."

The CoHesion Interface expands the utility of the EnSite and Sensei systems to provide physicians with a more comprehensive and easy-to-use remote navigation and mapping system for electrophysiology procedures. The EnSite system provides visualization and localization or detection of EP catheters in 3D space within the heart chamber, while the Sensei system is designed to permit remote movement of catheters in 3D. By integrating both products, Hansen Medical believes physicians should be able to navigate more instinctively within the 3D cardiac space because the system enables visualization and catheter movement in 3D, which may lead to greater accuracy of movement during catheter-based EP procedures.

St. Jude Medical's EnSite system is an advanced computer-based technology for mapping the electric activity for the heart, and for localizing and visualizing electrophysiology catheters in real time. The EnSite system creates 3D graphical displays of cardiac structures and arrhythmias, and enables catheter navigation without the use of fluoroscopy. Additionally, the EnSite system's open platform allows physicians to use their preferred therapy approach with diagnostic and ablation catheters of their choice.

The Sensei system uses flexible medical robotics technology to provide stable and predictable control of catheter movement inside the heart. This innovative technology is designed to provide fine catheter control while mapping in 3D to enhance the physician's ability to access hard-to-reach anatomy, and to maintain stability during interventional procedures. The physician workstation is adaptable to existing EP procedure rooms and can be placed away from the field of direct radiation. The disposable Artisan(TM) Control Catheter is comprised of inner and outer steerable guide catheters that accommodate existing pre-approved percutaneous catheters.

About Hansen Medical, Inc.

Hansen Medical, based in Mountain View, Calif., was founded in 2002 to develop products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the Sensei Robotic Catheter system, is cleared by the FDA for manipulation and control of certain mapping catheters in electrophysiology procedures. The safety and effectiveness of the Sensei system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation, have not been established. Additional information can be found at www.hansenmedical.com.

This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, beliefs, expectations, objectives and future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements about plans for integrating technologies, beliefs about the future benefits of new products and expectations about the possible results from the use of new products. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, the risks and uncertainties inherent in our business related to; potential safety and regulatory issues; the scope of potential use of current and future products; competition from other companies; and our ability to successfully market and support our products. These and other risks are described in greater detail under the heading "Risk Factors" contained in Item 1A of our Quarterly Report on Form 10Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission (SEC) and the risks discussed in our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

* The CoHesion Interface is under 510(k) review by the U.S. Food & Drug Administration and is not yet commercially available in the United States.

"Hansen Medical," "Sensei," "Artisan," "Hansen Artisan," as well as the Hansen Medical "heart design" are trademarks of Hansen Medical, Inc.

EnSite is a trademark of St. Jude Medical.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=667448

Media Contact: Amy Cook 925.552.7893 Email Contact Investor Contact: Steven Van Dick 650.404.5800 Email Contact

Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024

Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024